Systemic 7,8-Dihydroxyflavone Treatment Protects Immature Retinas Against Hypoxic-Ischemic Injury via Müller Glia Regeneration and MAPK/ERK Activation | Zendy

Hsiu-Mei Huang | Zendy; Chao Huang | Zendy; MengHan Tsai | Zendy; Linda Yi-Chieh Poon | Zendy; Ying-Chao Chang | Zendy

Open Access

Systemic 7,8-Dihydroxyflavone Treatment Protects Immature Retinas Against Hypoxic-Ischemic Injury via Müller Glia Regeneration and MAPK/ERK Activation

Author(s) -

Hsiu-Mei Huang,

Chao Huang,

MengHan Tsai,

Linda Yi-Chieh Poon,

Ying-Chao Chang

Publication year - 2018

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.18-23792

Subject(s) - neuroprotection , neurotrophic factors , mapk/erk pathway , neurogenesis , glial cell line derived neurotrophic factor , retina , medicine , biology , kinase , pharmacology , endocrinology , neuroscience , microbiology and biotechnology , receptor

Perinatal hypoxic-ischemic (HI) injury causes significant damages in the immature retina. The brain-derived neurotrophic factor is well known for its neuroprotective role but has limited clinical applications. A selective agonist of tyrosine kinase receptor B, 7,8-dihydroxyflavone (DHF), is a powerful therapeutic tool, when administered systemically. However, it remains unclear whether DHF treatment can protect the immature retinas against HI injury.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research